Alcon to Acquire Exclusive US Commercialization Rights to Novartis’ Simbrinza

 Alcon to Acquire Exclusive US Commercialization Rights to Novartis’ Simbrinza

Alcon to Acquire Exclusive US Commercialization Rights to Novartis’ Simbrinza

Shots:

  • Novartis to receive $355M following the closure of acquisition, which is expected to occur in Q2’21. The acquisition expands existing Alcon’s ophthalmic portfolio and strengthens its footprints in the US
  • The companies will initiate a transition period where Novartis will continue to sell Simbrinza and transfer the profit to Alcon. Following the transition period, Alcon expects to manufacture & commercialize Simbrinza in the US while Novartis will retain all rights (Ex-US)
  • Additionally, Alcon has launched Systane Hydration MDPF lubricant eye drops and is now available in a multi-dose bottle helps to minimize microbial contamination

Click here to­ read full press release/ article | Ref: Business Wire | Image: Medical Product Outsourcing

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post